Long‐term complete remissions of refractory severe idiopathic immune thrombocytopenia treated with daratumumab: A case series.

Autor:	Strüßmann, T., Heinz, J., Wäsch, R., Jung, J., Engelhardt, M., Duyster, J., Finke, J., Duque‐Afonso, J., Marks, R.
Předmět:	HAIRY cell leukemia IDIOPATHIC thrombocytopenic purpura THROMBOPOIETIN receptor agonists MANTLE cell lymphoma LITERATURE reviews
Zdroj:	British Journal of Haematology; Oct2024, Vol. 205 Issue 4, p1618-1621, 4p
Abstrakt:	The article in the British Journal of Haematology discusses the treatment of refractory severe idiopathic immune thrombocytopenia (ITP) with daratumumab, an anti-CD38 antibody. The study reports on a case series of seven patients who received daratumumab treatment, with four patients achieving sustained complete remission. The findings suggest that daratumumab may be a valid treatment option for refractory ITP patients, leading to durable responses in some cases. Additional data from prospective clinical trials are needed to further evaluate the efficacy of daratumumab in treating ITP. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text